Steven M. Larson

60.9k citations

724 papers · 44.1k indexed · 11 hit papers · h-index 111

Impact in

Radiology, Nuclear Medicine and Imaging top 0.01%
- Medical Imaging Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- Monoclonal and Polyclonal Antibodies Research
Radiation top 0.05%
- Advanced Radiotherapy Techniques

Papers in

Radiology, Nuclear Medicine and Imaging 466
- Radiopharmaceutical Chemistry and Applications 287
- Medical Imaging Techniques and Applications 177
- Monoclonal and Polyclonal Antibodies Research 105
- Radiomics and Machine Learning in Medical Imaging 78
Pulmonary and Respiratory Medicine 237
- Prostate Cancer Treatment and Research 97
- Medical Imaging and Pathology Studies 53

Co-authors: John L. Humm Heiko Schöder Mithat Gönen Henry Yeung Yusuf E. Erdi Howard I. Scher Jorge A. Carrasquillo Ronald D. Finn
Journals: Journal of Clinical Oncology (67 papers)Journal of Nuclear Medicine (47 papers)European Journal of Nuclear Medicine and Molecular Imaging (20 papers)Nuclear Medicine and Biology (17 papers)Clinical Cancer Research (14 papers)
Partner nations: United States Germany Sweden

In The Last Decade

Steven M. Larson

707 papers receiving 42.7k citations

Hit Papers

11 papers align trajectories log scale

2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer 2025 · 16 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2025 Thyroid
2015 Nature reviews. Cancer
2014 Science Translational Medicine
2013 New England Journal of Medicine
2011 Journal of Clinical Investigation
2010 The Lancet
2007 Clinical Cancer Research
2006 PubMed
2005 Clinical Cancer Research
2003 Nature Medicine
2000 International Journal of Radiation Oncology*Biology*Physics

Peers

Countries citing papers authored by Steven M. Larson

Since Specialization

Citations

This map shows the geographic impact of Steven M. Larson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven M. Larson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven M. Larson more than expected).

Fields of papers citing papers by Steven M. Larson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven M. Larson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven M. Larson. The network helps show where Steven M. Larson may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Steven M. Larson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Steven M. Larson Line = papers co-authored together Steven M. Larson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer Theranostics ·MG Sullentrup, Edward K. Fung, Sang Gyu Lee, Sébastien Monette, Hong Xu, Hong-Fen Guo, Justin R. Fogarty, Ouathek Ouerfelli, Achim A. Jungbluth, Heiko Schöder, Steven M. Larson, Nai‐Kong V. Cheung, Sarah M. Cheal, Darren R. Veach	2025	2
2	Life-threatening Mast Cell Activation and Anaphylaxis in Mast Cell Leukemia and the Role of Omalizumab Terese Hammond, 中尾充宏, A. Bermond, Steven M. Larson, Mariana Castells	2024	1
3	Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response Molecular Cancer Research ·Бескоровайная Татьяна Сергеевна, Meng Ma, Mesude Bicak, Darren R. Veach, Katharina Lückerath, Gabriel Adrian, Michael R. McDevitt, Teja Kalidindi, Julie E. Park, Ken Herrmann, Diane S. Abou, Xiuhui Ma, Norbert Peekhaus, Robert J. Klein, Robert Damoiseaux, Steven M. Larson, Hans Lilja, Daniel L.J. Thorek, David Ulmert	2023	2
4	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting The Prostate ·Andrea K. Miyahira, Kenneth J. Pienta, John W. Babich, Neil H. Bander, Jérémie Calais, Peter L. Choyke, Michael S. Hofman, Steven M. Larson, Frank I. Lin, Michael J. Morris, Martin G. Pomper, Shahneen Sandhu, Howard I. Scher, Scott T. Tagawa, Scott Williams, Howard R. Soule	2020	21
5	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy Proceedings of the National Academy of Sciences ·Mesude Bicak, Katharina Lückerath, Teja Kalidindi, Michael E. Phelps, Sven‐Erik Strand, Michael J. Morris, Caius G. Radu, Robert Damoiseaux, Mari Peltola, Norbert Peekhaus, Huawei Pan, Darren R. Veach, Mariaconsiglia Ferriero, Steven M. Larson, Hans Lilja, Michael R. McDevitt, Robert J. Klein, David Ulmert	2020	18
6	Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer Clinical Cancer Research ·Daniel L.J. Thorek, Anson T. Ku, Nicholas Mitsiades, Darren R. Veach, Philip A. Watson, Lojayn Elsaeed, Sven‐Erik Strand, Sai Kiran Sharma, Jason S. Lewis, Diane S. Abou, Hans Lilja, Steven M. Larson, Michael R. McDevitt, David Ulmert	2018	21
7	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer Nature Communications ·Michael R. McDevitt, Daniel L.J. Thorek, Takeshi Hashimoto, Tatsuo Gondo, Darren R. Veach, Sai Kiran Sharma, Teja Kalidindi, Diane S. Abou, Philip A. Watson, Bradley J. Beattie, Thais Agut Quijano, Sven‐Erik Strand, Jason S. Lewis, Peter T. Scardino, Howard I. Scher, Hans Lilja, Steven M. Larson, David Ulmert	2018	39
8	Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex Molecular Cancer Therapeutics ·Sarah M. Cheal, Hong Xu, Hong-Fen Guo, Pat Zanzonico, Steven M. Larson, Nai‐Kong V. Cheung	2014	45
9	Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer Clinical Cancer Research ·Scott T. Tagawa, Matthew I. Milowsky, Michael J. Morris, Shankar Vallabhajosula, Paul J. Christos, Naveed Akhtar, Joseph R. Osborne, Stanley J. Goldsmith, Steven M. Larson, Neeta Pandit Taskar, Howard I. Scher, Neil H. Bander, David M. Nanus	2013	308
10	Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen Cancer Discovery ·David Ulmert, Michael J. Evans, Jason P. Holland, Samuel L. Rice, John Wongvipat, Kim Pettersson, Per-Anders Abrahamsson, Peter T. Scardino, Steven M. Larson, Hans Lilja, Jason S. Lewis, Charles L. Sawyers	2012	58
11	Novel Mechanistic Insights into Arginine Deiminase Pharmacology Suggest ¹⁸F-FDG Is Not Suitable to Evaluate Clinical Response in Melanoma Journal of Nuclear Medicine ·Lars Stelter, Michael J. Evans, Achim A. Jungbluth, Pat Zanzonico, Gerd Ritter, Thomas W. Ku, Eric Rosenfeld, John S. Bomalaski, Lloyd J. Old, Steven M. Larson	2012	14
12	Five-Year Survival Is Similar in Thyroid Cancer Patients with Distant Metastases Prepared for Radioactive Iodine Therapy with either Thyroid Hormone Withdrawal or Recombinant Human TSH The Journal of Clinical Endocrinology & Metabolism ·Frank Gernand, Richard J. Robbins, James A. Fagin, Steven M. Larson, R. Michael Tuttle	2011	70
13	Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen Proceedings of the National Academy of Sciences ·Michael J. Evans, Peter Smith‐Jones, John Wongvipat, ROSANNA WARREN, Sae Kim, Neil H. Bander, Steven M. Larson, Charles L. Sawyers	2011	247
14	Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer Journal of Clinical Oncology ·Daniel C. Danila, Michael J. Morris, Johann S. de Bono, Charles J. Ryan, Samuel R. Denmeade, Matthew R. Smith, Mary-Ellen Taplin, Glenn J. Bubley, Thian Kheoh, Christopher M. Haqq, Arturo Molina, Aseem Anand, S Liberson, Steven M. Larson, Lawrence H. Schwartz, Martin Fleisher, Howard I. Scher	2010	318
15	Imaging Expression of the Human Somatostatin Receptor Subtype-2 Reporter Gene with ⁶⁸Ga-DOTATOC Journal of Nuclear Medicine ·Hanwen Zhang, Maxim A. Moroz, Inna Serganova, Thomas W. Ku, Ruimin Huang, Jelena Vider, Helmut R. Maëcke, Steven M. Larson, Ronald G. Blasberg, Peter Smith‐Jones	2010	59
16	Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning The Journal of Clinical Endocrinology & Metabolism ·Richard J. Robbins, Qiang Wan, Ravinder K. Grewal, Roland Reibke, Mithat Gönen, H. William Strausś, R. Michael Tuttle, William D. Drucker, Steven M. Larson	2006	403
17	A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. PubMed ·Chaonan Shi, Mithat Gönen, Henry Yeung, Homer A. Macapinlac, Steven M. Larson	2006	22
18	Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes Cancer Research ·T. Gade, Waleed Hassen, Elmer Santos, Gertrude Gunset, Aurore Saudemont, Michael Gong, Renier J. Brentjens, 美千代辻, Matthias T. Stephan, Jolanta Stefanski, Clay Lyddane, Joseph R. Osborne, Ian M. Buchanan, Simon J. Hall, Warren D.W. Heston, Isabelle Rivière, Steven M. Larson, Jason A. Koutcher, Michel Sadelain	2005	93
19	Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients British Journal of Clinical Pharmacology ·P. Tanswell, Pilar Garin‐Chesa, Wolfgang J. Rettig, Sydney Welt, Chaitanya Divgi, Ephraim S. Casper, Ronald D. Finn, Steven M. Larson, Lloyd J. Old, Andrew M. Scott	2001	1
20	Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients British Journal of Clinical Pharmacology ·P. Tanswell, Pilar Garin‐Chesa, Wolfgang J. Rettig, Sydney Welt, Chaitanya Divgi, Ephraim S. Casper, Ronald D. Finn, Steven M. Larson, Lloyd J. Old, Andrew M. Scott	2001	37

About Steven M. Larson

Steven M. Larson is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine, Oncology, Radiation and Cancer Research, having authored 724 papers that have together received 44.1k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (287 papers), Medical Imaging Techniques and Applications (177 papers), Monoclonal and Polyclonal Antibodies Research (105 papers), Prostate Cancer Treatment and Research (97 papers), Radiomics and Machine Learning in Medical Imaging (78 papers), Medical Imaging and Pathology Studies (53 papers), Thyroid Cancer Diagnosis and Treatment (50 papers) and Neuroblastoma Research and Treatments (47 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (22.2k citations), Radiation (3.7k citations), Pulmonary and Respiratory Medicine (13.0k citations), Oncology (10.5k citations) and Endocrinology, Diabetes and Metabolism (4.6k citations). Steven M. Larson has collaborated with scholars based in United States, Germany and Sweden. Frequent co-authors include John L. Humm, Heiko Schöder, Mithat Gönen, Henry Yeung, Yusuf E. Erdi, Howard I. Scher, Jorge A. Carrasquillo, Ronald D. Finn, Pat Zanzonico and Richard J. Robbins. Their work appears in journals such as Journal of Clinical Oncology, Journal of Nuclear Medicine, European Journal of Nuclear Medicine and Molecular Imaging, Nuclear Medicine and Biology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact